Form 4: Sangamo Therapeutics Director James R. Meyers Receives Significant Equity Grants

Sangamo Therapeutics, Inc. Director James R. Meyers was granted 25,000 restricted stock units and options to purchase 50,000 shares of common stock, aligning his interests with the company's long-term performance.

Summary

• James R. Meyers, a Director of Sangamo Therapeutics, Inc. (SGMO), reported the acquisition of equity securities on June 12, 2025.
• He was granted 25,000 shares of common stock in the form of Restricted Stock Units (RSUs) at an acquisition price of $0 per share.
• These RSUs are set to fully vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders, contingent on his continuous service.
• Additionally, Mr. Meyers received stock options to purchase 50,000 shares of common stock with an exercise price of $0.503 per share.
• These stock options are immediately exercisable, but the underlying shares are subject to repurchase rights by the Issuer if unvested upon cessation of service.
• The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, also subject to continuous service.
• Following these transactions, Mr. Meyers beneficially owns 99,600 shares of common stock and 50,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports standard equity compensation for a director, which is generally a neutral event but can be seen as slightly positive as it aligns the director's interests with shareholders and aids in retention.

Positives

• The grant of RSUs and stock options to Director James R. Meyers aligns his financial interests with the long-term performance and success of Sangamo Therapeutics.
• The immediate exercisability of the stock options, despite vesting conditions, provides flexibility to the director.

Risks

• The vesting of both the RSUs and stock options is subject to the Reporting Person's Continuous Service, meaning forfeiture could occur if service ceases before vesting is complete.
• Unvested shares purchased under the stock option are subject to certain repurchase rights by the Issuer upon cessation of continuous service.

Future Outlook

The RSU grant is expected to fully vest by June 12, 2026, or prior to the 2026 annual meeting, while the stock options will vest in 12 equal monthly installments following the grant date, both contingent on the director's continuous service.

Industry Context

This Form 4 filing is a standard disclosure of insider equity compensation, common across publicly traded companies, particularly in the biotechnology sector like Sangamo Therapeutics, to incentivize and retain key personnel.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of equity securities by Sangamo Therapeutics, Inc. to James R. Meyers, a Director of the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The issuance of new shares (upon RSU vesting and option exercise) could lead to minor dilution, but the grants are intended to align director interests with shareholder value creation.
• Employees: The equity incentive plan (2018 EIP) is a standard mechanism for attracting and retaining talent, potentially benefiting overall employee morale and performance.

Next Steps

• Continued vesting of 25,000 Restricted Stock Units until full vesting on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders.
• Continued vesting of 50,000 stock options in 12 successive equal monthly installments following the grant date.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Options, Director Compensation, Sangamo Therapeutics, SGMO, Beneficial Ownership, Vesting Schedule